The Marked Chart Wire · Series of events
Series of events · Tempus AI
Tempus AI shares dip before strong earnings and study data
The stock faced valuation concerns before new clinical data and a beat-and-raise earnings report.
Updated
What happened, in order
Times are Eastern-
Where it began
Shares fall on rating
Shares declined after Goldman Sachs issued a neutral rating with a lower price target and the CEO sold shares.
-
Lung cancer data
The company shared trial data from over 60,000 cases showing its AI identified over 80 percent of biomarkers.
Read the story -
Latest
Earnings beat and raise
Third-quarter revenue hit $411.5 million, beating forecasts, and full-year 2026 guidance was raised to $1.600 billion.
Read the story
How they connect
Initial valuation concerns emerged before the company released positive clinical trial data. This was followed by a quarterly earnings report that exceeded expectations and raised annual guidance.
The stocks in this series
Prices from Before the open · based on Fri close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.